Why Big Pharma sees the abortion drug legal fight as a grave business risk

Published



One year after the nation learned of the Supreme Court‘s intent to peel back federal protections for abortions via a leaked draft opinion, a new legal fight over the approval of a common abortion drug has ignited condemnation from nearly every corner of the pharmaceutical industry.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.